Skip to main content

Table 3 Influencing factors on longitudinal medication costs across ILD subtypes

From: Cost drivers in the pharmacological treatment of interstitial lung disease

 

IPF

PF-ILD

Sarcoidosis

Other ILD

OR [95% CI]

OR [95% CI]

OR [95% CI]

OR [95% CI]

Male

1.03 [0.65–1.41]

1.73 [1.27–2.20]*

2.56 [1.58–3.54]*

1.02 [0.64–1.40]

Former/current smoker

1.25 [0.92–1.59]

0.57 [0.13–1.00]

2.62 [1.79–3.46]*

1.00 [0.59–1.41]

Age

0.99 [0.97–1.01]

1.05 [1.03–1.07]*

1.03 [0.99–1.07]

0.99 [0.97–1.01]

FVC % pred. At baseline

1.00 [0.99–1.00]

1.00 [0.99–1.01]

1.00 [0.97–1.03]

0.99 [0.98–1.00]

Disease duration

1.11 [1.03–1.19]*

0.92 [0.88–0.96]*

0.94 [0.89–0.99]*

0.93 [0.89–0.97]*

Comorbidity sum score

1.04 [0.96–1.13]

1.52 [1.31–1.74]*

1.60 [1.23–1.97]*

1.24 [1.11–1.38]*

T1

1.24 [0.87–1.61]

2.22 [1.72–2.71]*

0.77 [0.42–1.12]

1.05 [0.67–1.42]

T2

5.95 [5.59–6.30]*

11.8 [11.3–12.3]*

2.09 [1.64–2.54]*

6.46 [6.05–6.86]*

  1. *p-value < 0.05